TAK - What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? | Benzinga
Monday, Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
In March 2021, Takeda and Ovid Therapeutics Inc (NASDAQ:OVID) entered into an exclusive agreement under which Takeda secured global rights from Ovid to develop and commercialize soticlestat for developmental and epileptic encephalopathies.
Related: Japan Pharma Giant Takeda’s Anti-Seizure Treatment Flunks In Two Late-Stage Studies
At ...